Oncolytics Biotech® Receives Special Protocol Assessment Agreement from FDA for Phase 3 Clinical Trial of Pelareorep In Metastatic Breast Cancer

KeepHealthCare.ORG – Oncolytics Biotech® Receives Special Protocol Assessment Agreement from FDA for Phase 3 Clinical Trial of Pelareorep In Metastatic Breast Cancer CALGARY, Alberta and SAN DIEGO, May 10, 2018 Continue reading

FDA Grants Balixafortide Fast Track Designation for Treatment of Metastatic Breast Cancer Subset

KeepHealthCare.ORG – FDA Grants Balixafortide Fast Track Designation for Treatment of Metastatic Breast Cancer Subset The immunotherapy agent balixafortide (POL6326) has been granted Fast Track designation by the FDA in Continue reading

BRIEF-Celldex’S Metric Study In Metastatic Triple-Negative Breast Cancer Does Not Meet Primary Endpoint

KeepHealthCare.ORG – BRIEF-Celldex’S Metric Study In Metastatic Triple-Negative Breast Cancer Does Not Meet Primary Endpoint April 16 (Reuters) – Celldex Therapeutics Inc: * CELLDEX’S METRIC STUDY IN METASTATIC TRIPLE-NEGATIVE BREAST Continue reading

BRIEF-AstraZeneca says Updated Overall Survival Data For Lynparza(Olaparib) In Gbrca-Mutated Her2-Negative Metastatic Breast Cancer Presented At AACR

KeepHealthCare.ORG – BRIEF-AstraZeneca says Updated Overall Survival Data For Lynparza(Olaparib) In Gbrca-Mutated Her2-Negative Metastatic Breast Cancer Presented At AACR April 16 (Reuters) – AstraZeneca PLC: * UPDATED OVERALL SURVIVAL DATA Continue reading

Perioperative NSAIDs may prevent early metastatic relapse in post-surgical breast cancer patients

KeepHealthCare.ORG – Perioperative NSAIDs may prevent early metastatic relapse in post-surgical breast cancer patients According to new research conducted in mice by Whitehead Institute scientists, surgery in breast cancer patients, Continue reading

Palbociclib Combo Effective in Frontline Treatment of ER+, HER2- Postmenopausal Metastatic Breast Cancer

KeepHealthCare.ORG – Palbociclib Combo Effective in Frontline Treatment of ER+, HER2- Postmenopausal Metastatic Breast Cancer Palbociclib (Ibrance), a CDK 4/6 inhibitor, demonstrated significant efficacy in combination with the aromatase inhibitor letrozole Continue reading